scholarly journals The Effect of Dry Eye Disease on Scar Formation in Rabbit Glaucoma Filtration Surgery

2017 ◽  
Vol 18 (6) ◽  
pp. 1150 ◽  
Author(s):  
◽  
◽  
◽  
◽  
◽  
...  
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Scar Formation ◽  
Eye Disease ◽  
Filtration Surgery ◽  
Glaucoma Filtration Surgery

Lack of Social Support and Social Trust as Potential Risk Factors for Dry Eye Disease: JPHC-NEXT Eye Study

2018 ◽  
Author(s):  
Chi Hoang Viet Vu ◽  
Miki Uchino ◽  
Motoko Kawashima ◽  
Akihiro Nishi ◽  
Christopher A. German ◽  
...  
Keyword(s):  
Risk Factors ◽  
Social Support ◽  
Dry Eye ◽  
Potential Risk ◽  
Social Trust ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Potential Risk Factors

Hot Topics in Dry Eye Disease

2017 ◽  
Vol 23 (4) ◽  
pp. 608-623 ◽  
Author(s):  
Andrzej Grzybowski ◽  
Marcos Mendaro ◽  
Sebastian Dankert ◽  
Luis Bardeci ◽  
Pablo Chiaradia
Keyword(s):  
Dry Eye ◽  
Dry Eye Disease ◽  
Eye Disease

scholarly journals The role of KPI-121 0.25% in the treatment of dry eye disease: penetrating the mucus barrier to treat periodic flares

2021 ◽  
Vol 13 ◽  
pp. 251584142110127
Author(s):  
Preeya K. Gupta ◽  
Nandini Venkateswaran
Keyword(s):  
Drug Delivery ◽  
Dry Eye ◽  
Ocular Surface ◽  
Dry Eye Disease ◽  
Eye Disease ◽  
Eye Drops ◽  
Short Term ◽  
Short Term Treatment ◽  
Loteprednol Etabonate ◽  
Mucus Barrier

The tear film, which includes mucins that adhere to foreign particles, rapidly clears allergens and pathogens from the ocular surface, protecting the underlying tissues. However, the tear film’s ability to efficiently remove foreign particles during blinking can also pose challenges for topical drug delivery, as traditional eye drops (solutions and suspensions) are cleared from the ocular surface before the drug can penetrate into the conjunctival and corneal epithelium. In the past 15 years, there has been an increase in the development of nanoparticles with specialized coatings that have reduced affinity to mucins and are small enough in size to pass through the mucus barrier. These mucus-penetrating particles (MPPs) have been shown to efficiently penetrate the mucus barrier and reach the ocular surface tissues. Dry eye disease (DED) is a common inflammatory ocular surface disorder that often presents with periodic flares (exacerbations). However, currently approved immunomodulatory treatments for DED are intended for long-term use. Thus, there is a need for effective short-term treatments that can address intermittent flares of DED. Loteprednol etabonate, an ocular corticosteroid, was engineered to break down rapidly after administration to the ocular surface tissues and thereby reduce risks associated with other topical steroids. KPI-121 is an ophthalmic suspension that uses the MPP technology to deliver loteprednol etabonate more efficiently to the ocular tissues, achieving in animal models a 3.6-fold greater penetration of loteprednol etabonate to the cornea than traditional loteprednol etabonate ophthalmic suspensions. In clinical trials, short-term treatment with KPI-121 0.25% significantly reduced signs and symptoms of DED compared with its vehicle (placebo). Recently approved KPI-121 0.25%, with its novel drug delivery design and ease of use, has the potential to effectively treat periodic flares of DED experienced by many patients.

Sign in / Sign up

Export Citation Format

Share Document